Valanafusp Alpha - ArmaGen Technologies

Drug Profile

Valanafusp Alpha - ArmaGen Technologies

Alternative Names: AGT-181; cTfRMAb-IDUA murine fusion protein; HIRMAb-IDUA; IgG-alpha-L-iduronidase fusion protein; IgG-IDUA fusion protein; Recombinant human insulin receptor monoclonal antibody-fused alpha-L-iduronidase; Valanafusp

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArmaGen Technologies
  • Class Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mucopolysaccharidosis I

Most Recent Events

  • 02 Aug 2018 ArmaGen completes an extension phase I trial for Mucopolysaccharidosis I in USA (IV) (NCT02597114)
  • 24 Jun 2018 Biomarkers information updated
  • 08 Feb 2018 Updated efficacy and adverse events data from a phase II trial in Mucopolysaccharidosis I released by ArmaGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top